• FDA approves Mylotarg for treatment of acute myeloid leukemia worldpharmanews
    September 04, 2017
    The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).
PharmaSources Customer Service